News

As early bird registration remains open until 27 March, AusMedtech 2026 is steadily coming into view. For many in the sector, it is not just about the formal presentations but also the in-between moments when conversations unfold, and ideas begin to take shape.

Racura Oncology (ASX:RAC) has reached a key clinical milestone with the successful dosing of a patient in Hong Kong, marking both geographic expansion and the completion of the first cohort in its early-stage trial of RC220, a candidate designed to deliver both anticancer activity and cardioprotection.

Driving south along Blackburn Road in Clayton, Melbourne, Professor Robyn Ward, Deputy Vice-Chancellor for Research and Enterprise at Monash University and Chair of the Pharmaceutical Benefits Advisory Committee, sees more than an unremarkable stretch of suburban road.

Immutep (ASX:IMM) has reported encouraging early progress in developing a first-in-class therapy that could reshape how autoimmune diseases are treated, following completion of a key stage in its first human clinical trial.

Orthocell (ASX:OCC) has reported that its Remplir nerve repair device has been used in 23 surgical procedures on Ukrainian soldiers in combat, marking a significant real-world application of the company’s regenerative medicine technology in a conflict setting.

AdAlta (ASX:1AD) has moved to strengthen its strategic and market-facing capabilities with the appointment of experienced corporate executive Fadi Diab to its Board as a non-executive director.

In a move that signals growing momentum for Australia’s role in advanced therapeutics, Viral Vector Manufacturing Facility has entered into a licensing agreement with global cell and gene therapy specialist OXB, opening the door to critical viral vector technologies and strengthening the nation’s position in a rapidly expanding field.

Australia’s life sciences sector has welcomed a major national push to strengthen research, development and innovation, with industry leaders urging coordinated government action to secure the country’s economic and health future.

A coin-sized implantable sensor designed to monitor pressure inside the brain has been approved for use in Australia, offering clinicians a new way to manage hydrocephalus and potentially reducing the need for repeated scans and surgical interventions.

The Sydney-based medical device company announced that its non-renounceable entitlement offer had raised about $2 million and was fully subscribed, including the underwriting commitment from Bell Potter Securities.

Firebrick Pharma has appointed experienced pharmaceutical executive Nilesh Wadhwa to lead its global business development and licensing efforts as the company pushes to rapidly expand international approvals and sales of its Nasodine product range.

The Perth and San Francisco-based biotechnology company announced that discussions with the FDA confirmed key elements of the clinical trial required to support a future New Drug Application for the therapy.